Loading...
Please wait, while we are loading the content...
Similar Documents
Ustekinumab in psoriatic arthritis: need for studies from real-world evidence
| Content Provider | Scilit |
|---|---|
| Author | Queiro, Rubén Coto-Segura, Pablo |
| Copyright Year | 2018 |
| Description | Ustekinumab (UST) is a recently approved drug for the treatment of psoriatic arthritis (PsA). The ACR response rates in randomized clinical trials (RCTs) with this drug have been slightly lower than that reported in RCTs of anti-TNF and anti-IL17 therapies. Therefore, the position that this drug may occupy in the treatment algorithms of PsA is not clear. More information is needed on the true efficacy of this agent under real clinical practice conditions. In this review of real-world evidence studies, it is shown that UST is effective and safe to treat PsA; nevertheless, it is necessary to homogenize the way in which the main outcomes and treatment objectives of these studies are presented. |
| Related Links | https://www.tandfonline.com/doi/pdf/10.1080/14712598.2018.1504919?needAccess=true |
| Ending Page | 935 |
| Page Count | 5 |
| Starting Page | 931 |
| ISSN | 14712598 |
| e-ISSN | 17447682 |
| DOI | 10.1080/14712598.2018.1504919 |
| Journal | Expert Opinion on Biological Therapy |
| Issue Number | 9 |
| Volume Number | 18 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2018-07-31 |
| Access Restriction | Open |
| Subject Keyword | Journal: Expert Opinion On Biological Therapy Rheumatology Psoriasis Psoriatic Arthritis Ustekinumab Real-world Evidence |
| Content Type | Text |
| Subject | Drug Discovery Clinical Biochemistry Pharmacology |